Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. (Q44348524)
Jump to navigation
Jump to search
scientific article published in March 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. |
scientific article published in March 2003 |
Statements
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival (English)
Raeve De Hendrik
Mark J Perry
Anja Hijzen
Claire M Shipman
Jennifer Lippitt
Jonathan Green
Eric Van Marck
Ben Van Camp
Karin Vanderkerken
1 reference